Investor Presentation Q2 2018 TSXv: NDVA 2/24 I N V E S T O R P - PowerPoint PPT Presentation

Investor Presentation Q2 2018

TSXv: NDVA 2/24 I N V E S T O R P R E S E N TAT I O N The information contained herein, together with any amendments or supplements and any other information that may be furnished by the company, includes forward-looking information. Such information is based on assumptions as to future events that are inherently uncertain and subjective. The company makes no representation or warranty as to the attainability of such Forward assumptions, including the completion of a fjnancing or as to whether future results will occur as projected. Looking It must be recognized that the projections of the Statement company’s future performance are necessarily subject to a high degree of uncertainty, that actual results can be expected to vary from the results projected and that such variances may be material and adverse. Prospective investors are expected to conduct their own investigation with regard to the company and its prospects. This presentation does not constitute an ofger to sell or a solicitation of an ofger to buy any security.

TSXv: NDVA 3/24 I N V E S T O R P R E S E N TAT I O N 01 – Executive Summary _________________________________________ 4 SUMMARY Growing Demand for Medical Cannabis _______________________ 6 02 – Recreational Cannabis Market ________________________________ 7 INVESTING IN CANNABIS Insuffjcient Supply of Cannabis _______________________________ 8 Table of Talented and Experienced Team ______________________________ 10 High Quality Products _______________________________________ 11 03 – Contents INDIVA ADVANTAGES Our Corporate Identity ______________________________________ 14 Customer Acquisition Strategies ______________________________ 15 London Facility _____________________________________________ 17 04 – Production Facility Pictures __________________________________ 19 LONDON FACILITY Path to 40+ Million Grams ____________________________________ 20 London Operating Expenses __________________________________ 22 05 – Capex/Use of Funds _________________________________________ 23 USE OF FUNDS AND COST BREAKDOWN, LONDON ONTARIO Comparables _______________________________________________ 24

TSXv: NDVA 4/24 I N V E S T O R P R E S E N TAT I O N NEAR TERM CATALYSTS Sales Expansion Processing Facility Fully funded expansion Sales license is Fully funded processing to 40, 000 square feet expected as early as facility planned for 2019. underway and to be Q2 of 2018 and sales Facility to produce INDIVA, completed in Q4 of 2018. expected to start in Bhang, DeepCell and Q4 of 2018 other cannabis products. Executive Summary STRONG FUNDAMENTALS • Award-winning cannabis products • State-of-the-art GMP-standard indoor production facility • Fully funded expansion • Experienced Master Grower with award- winning strains and loyal 1000+ patient base. • Experienced management team, passionate about helping people and protecting investors

Investing in INDIVA London USE OF FUNDS AND COST Executive BREAKDOWN Cannabis Advantages Facility Summary 05 01 02 03 04 02 Investing in Q2 2018 Cannabis

TSXv: NDVA 6/24 I N V E S T O R P R E S E N TAT I O N Health Canada’s Projected Registered Patients Actual Registered Patients 450,000 400,000 Registered Patients December 2017: registered 350,000 patients exceeds Health 300,000 Canada’s 2022 projection 250,000 200,000 150,000 100,000 50,000 Growing 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Demand GROWTH RATE OF MEDICINAL CANNABIS USERS IS HIGHER THAN EXPECTED for Medical Health Canada projected 450,000 patients At September 2017, there were 269,502 Cannabis will be using cannabis at $1.3 billion annual patients registered, which is a 14% quarter- revenue by 2024. over-quarter increase & approximately equal 11,058 to Health Canada’s projection for 2022 physicians have authorized patient access to medicinal 6,000,000 marijuana 5,000,000 4,000,000 269,502 3,000,000 registered patients 2,000,000 in total to date 1,000,000 Multiple Risk of Migraine Life Stress Sclerosis Epilepsy Cancer Low BMI Severe Pain Depression Headaches Insomnia Anxiety Arthritis Hypertension (Elevated) 11,000 (approx.) new patients per month (~5% month- POTENTIAL MARKET Source: Health Canada, Statistics Canada, Canadian Community Health Survey, medicalmarijuana.ca over-month growth)

TSXv: NDVA 7/24 I N V E S T O R P R E S E N TAT I O N Daily Weekly Monthly Occasionally Non-Consumers Potential Customer 7% 4% 17% SIZE AND MAKEUP OF THE CANADIAN 3% RECREATIONAL MARKET 8% According to the Deloitte Survey, the size of the Canadian recreational cannabis market could be as much as $8.7 billion per year, or similar to the size of the Canadian spirit market. 61% Recreational Cannabis Source: Deloitte, PBO Consumption (Metric Tonnes) Users (Thousands) Market 410 1500 300 1100 175 55 20 10 Once Less than once a month 1-3 Times per month At least once a week Daily ANNUAL CANNABIS USERS Aged 15 and over, Canada excluding Territories, Mid-point Estimates, 2018 AND CONSUMPTION

TSXv: NDVA 8/24 I N V E S T O R P R E S E N TAT I O N Number of licences issued by province YT 0 NU NT 0 0 NL Insuffjcient 0 BC Supply of 22 AB MB QC 5 2 Cannabis 6 PE SK 1 ON 4 56 NS 3 NB 3 Current Production Health Canada Market Health Canada Market Data from Q3 2017 Data from Q3 2017 • 102 existing LPs • Dry fmowers: 6.3mm grams sold, 38.9mm grams • Supplying even the low end of the • Current production insuffjcient in inventory estimate of the recreational cannabis to meet demand • Oil: 9.3mm grams sold, 11.1mm grams inventory market would require the production • 45 Sales Licenses issued • 269,502 registered clients at December 31, 2017 of over 700mm grams of cannabis (37 companies) • Prices range from $1.75/gram to $15/gram annually

Investing in INDIVA London USE OF FUNDS AND COST Executive BREAKDOWN Cannabis Advantages Facility Summary 05 01 02 03 04 03 INDIVA Q2 2018 Advantages

TSXv: NDVA 10/24 I N V E S T O R P R E S E N TAT I O N FINANCE & CORPORATE DEVELOPMENT CREATIVE – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – Niel Marotta President & CEO, Tom Borowicz Chief Brand Offjcer • Over 30 years of experience in marketing, Director, Founder branding, print/digital advertising and design • Managed over $1 Billion across several with Fortune 500 companies industries Involved in capital raises and M&A transactions exceeding $1 Billion PRODUCTION – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – LEGAL & BUSINESS DEVELOPMENT Pete Young Master Grower, Founder – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – Koby Smutylo COO, General Counsel, • Grow Team: 15+ years of experience producing medicinal strains for hundreds of patients Talented & Director, Founder • International recognition and multiple product • Koby is a seasoned lawyer and has acted as awards counsel to private and public companies Experienced • Helped fjnance and license an ACMPR LP Team PROJECT MANAGEMENT – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – FINANCE Jose Laurentino Chief Technology Offjcer – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – • 20+ years in agricultural project development Jennifer Welsh Chief Financial Offjcer including indoor and greenhouse expertise • Managed a global fjnance team for eight years as Corporate Controller of a TSX listed company • Former consultant for a publicly traded LP

TSXv: NDVA 11/24 I N V E S T O R P R E S E N TAT I O N INDIVA High Quality Products

TSXv: NDVA 12/24 I N V E S T O R P R E S E N TAT I O N Products Powered by INDIVA

TSXv: NDVA 13/24 I N V E S T O R P R E S E N TAT I O N Products Powered by INDIVA